ClinicalTrials.gg
CompletedNCT04565990SOMBREROUpdated May 1, 2025Results posted

A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study

A Phase 3 interventional study of Selexipag in Hypertension, Pulmonary, sponsored by Actelion. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Hypertension, Pulmonary by Johnson & Johnson — 1 open to participants now, 2 under way, 2 of them phase 3. Hypertension, Pulmonary · Johnson & Johnson.

Enrollment
20th of 27
43 · median 67
Started
2021
with 1 other
Phase 3
13 of 29
1 open now
Registered
28th of 29
by date

Among the 29 studies in Hypertension, Pulmonary by Johnson & Johnson, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2021, is one of 13 in phase 3, and was the 28th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

1 of the 29 studies in Hypertension, Pulmonary by Johnson & Johnson is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Hypertension, Pulmonary by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term safety of selexipag while providing continued selexipag treatment for participants who were previously enrolled in an Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications for which a positive benefit-risk has been established.

03

Conditions studied

  • Hypertension, Pulmonary
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treated with selexipag at the end of a parent study and: a) the parent study has established efficacy with a favorable benefit/risk profile for the indication under investigation; b) participant may continue to benefit from treatment with selexipag; c) has completed the end of treatment (EOT) visit of the parent study; d) no alternative means of access to selexipag have been identified
  • Women of must use an acceptable method of throughout the study and until at least 1 month following the last dose of study intervention
  • Women of childbearing potential must have a negative urine (or serum if applicable) pregnancy test at screening on Day 1 or at the last visit of the parent study
  • Must sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Suspected or known pulmonary veno-occlusive disease
  • Known allergies, , or intolerance to selexipag or its
  • Interruption of study intervention for more than 14 days since the last dose of study intervention taken in the parent study
  • Female participant being pregnant, or breastfeeding, or planning to become pregnant at the time of screening and while enrolled in this study
  • Uncontrolled thyroid disease
  • Known and documented severe hepatic impairment, example, Class C
  • Taken any disallowed therapies, Concomitant Therapy before the planned first dose of study intervention: a) treatment with a strong CYP 2C8 inhibitor (example, gemfibrozil); b) treatment with oral prostacyclin analogs (example, beraprost, treprostinil) since the last dose of study intervention taken in the parent study; c) any treatment other than selexipag
  • Severe coronary heart disease or unstable angina, myocardial infarction within the last 6 months, decompensated cardiac failure if not under close medical supervision, severe arrhythmia, cerebrovascular events (example, , stroke) within the last 3 months, or congenital or acquired valvular defects with myocardial function disorders not related to PH
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Selexipag

    Participants will receive selexipag tablets twice daily with the dose strength corresponding to their individual maximum tolerated dose (iMTD) from the parent study.

    Drug: Selexipag

Interventions

  • Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily.

    Also known as: JNJ-67896049, ACT-293987

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs were reported. Adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days. Data includes all TEAEs irrespective of whether they were serious or non-serious.

    Time frame: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)

  2. Number of Participants With TEAEs Leading to Premature Discontinuation of Selexipag

    Number of participants with TEAEs leading to premature discontinuation of selexipag were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days.

    Time frame: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)

  3. Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

    Number of participants with TESAEs were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TESAEs were defined as TSAEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days.

    Time frame: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)

  4. Number of Participants With Treatment-emergent Deaths

    Number of participants with treatment-emergent deaths during the study were reported.

    Time frame: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)

  5. Number of Pregnant Females With Maternal Exposure to Selexipag

    Number of pregnant females with maternal exposure to selexipag were reported.

    Time frame: From Day 1 up to 30 days after last dose of drug (up to 29 months)

07

Results

Posted Nov 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneSelexipag
Started43
Completed36
Not completed7
Withdrew: Death5
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. Adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days. Data includes all TEAEs irrespective of whether they were serious or non-serious.

Time frame:
From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSelexipag
Number of Participants With Treatment-emergent Adverse Events (TEAEs)22
PrimaryNumber of Participants With TEAEs Leading to Premature Discontinuation of Selexipag

Number of participants with TEAEs leading to premature discontinuation of selexipag were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days.

Time frame:
From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Premature Discontinuation of Selexipag
ParticipantsSelexipag
Number of Participants With TEAEs Leading to Premature Discontinuation of Selexipag0
PrimaryNumber of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

Number of participants with TESAEs were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TESAEs were defined as TSAEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days.

Time frame:
From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsSelexipag
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)7
PrimaryNumber of Participants With Treatment-emergent Deaths

Number of participants with treatment-emergent deaths during the study were reported.

Time frame:
From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Deaths
ParticipantsSelexipag
Number of Participants With Treatment-emergent Deaths5
PrimaryNumber of Pregnant Females With Maternal Exposure to Selexipag

Number of pregnant females with maternal exposure to selexipag were reported.

Time frame:
From Day 1 up to 30 days after last dose of drug (up to 29 months)
Reported as:
Count of participants · Participants
Number of Pregnant Females With Maternal Exposure to Selexipag
ParticipantsSelexipag
Number of Pregnant Females With Maternal Exposure to Selexipag0

Adverse events

Collected over All cause mortality: From Day 1 up to 30 days after last dose of drug (up to 29 months), Other AEs and SAEs: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selexipag5/43 (11.6%)7/43 (16.3%)20/43 (46.5%)
Most frequent serious events
Most frequent serious events
EventSelexipag
Pulmonary Arterial HypertensionRespiratory, thoracic and mediastinal disorders3/43
Cardiac Failure AcuteCardiac disorders1/43
Covid-19 PneumoniaInfections and infestations1/43
PneumoniaInfections and infestations1/43
Subacute EndocarditisInfections and infestations1/43
SyphilisInfections and infestations1/43
Systemic SclerodermaMusculoskeletal and connective tissue disorders1/43
HypotensionVascular disorders1/43
Most frequent other events
Showing 10 of 36
Most frequent other events
EventSelexipag
Covid-19Infections and infestations4/43
Chronic GastritisGastrointestinal disorders2/43
PyrexiaGeneral disorders2/43
Respiratory Tract InfectionInfections and infestations2/43
AnaemiaBlood and lymphatic system disorders1/43
ThrombocytopeniaBlood and lymphatic system disorders1/43
Atrial FibrillationCardiac disorders1/43
Pericardial EffusionCardiac disorders1/43
Sinus TachycardiaCardiac disorders1/43
GoitreEndocrine disorders1/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)Selexipag
Mean50.6 ± 13.25
Age, Customized
Age, Customized(Participants)Selexipag
Adults (18-64 years)37
From 65 to 84 years6
>=85 years0
Sex: Female, Male
Sex: Female, Male(Participants)Selexipag
Female36
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selexipag
Hispanic or Latino0
Not Hispanic or Latino43
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selexipag
American Indian or Alaska Native0
Asian11
Native Hawaiian or Other Pacific Islander0
Black or African American0
White32
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Selexipag
BELARUS21
INDIA4
ROMANIA2
SOUTH KOREA4
TAIWAN3
UKRAINE9
08

Study locations

13 sites
  • The Republican Scientific-Practical Center ''Cardiology''
    Minsk, 220036, Belarus
  • Minsk Regional Clinical Hospital
    Minsk, 220143, Belarus
  • Sanjivani Hospitals
    Ahmedabad, 380015, India
  • Apollo Hospitals
    Chennai, 600006, India
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea Seoul St Marys Hospital
    Seoul, 06591, Korea, Republic of
  • Institutul de pneumoftiziologie Marius Nasta
    Bucuresti, 050152, Romania
  • Kaohsiung Veterans General Hospital
    Kaohsiung, 813, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Municipal Inst. Of Dnipropetrovsk Region. Council
    Dnipro, Ukraine
  • Health Care Municipal Institution City Clinical Hospital #13
    Kharkiv, Ukraine
  • State Institute Of Phthisiology And Pulmonology N.A. F.G. Yanovskiy Of Ams Ukraine
    Kyiv, 03680, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Nov 2023, 30 months.

Results were first posted in Nov 2024, 1 year after primary completion.

Of 31 phase 3 interventional studies under Hypertension, Pulmonary, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 83. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2020
First posted
Sep 28, 2020
StartActual
May 3, 2021
Primary completionActual
Nov 10, 2023
CompletionActual
Nov 10, 2023
Results first posted
Nov 20, 2024
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04565990
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Sep 28, 2020
Start date
May 3, 2021
Primary completion
Nov 10, 2023
Completion
Nov 10, 2023
Results posted
Nov 20, 2024
Last update
May 1, 2025

Study contacts

Actelion Clinical Trial
study director · Actelion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion